Introduction
Sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) are important signaling molecules which activate a family of related G protein coupled receptors (GPCR) called endothelial differentiation gene (Edg) receptors (Chun et al., 2002) . The receptors S1P 1 (Edg1), S1P 2 (Edg5), S1P 3 (Edg3), S1P 4 (Edg6) and S1P 5 (Edg8) bind S1P and regulate many cellular functions, including cell growth, proliferation, apoptosis, adhesion and differentiation (Pyne and Pyne, 2000; Spiegel and Milstien, 2003) .
A role for S1P receptors in regulating immune function was discovered when the mechanism of FTY720 ( Fig. 1 ) was elucidated. FTY720 is in clinical trials to prevent transplant rejection (Kiuchi et al., 2000) and is metabolized rapidly in the blood to the corresponding phosphate ester, FTY720-P ( Fig. 1 ), which is a full agonist of S1P 1 , S1P 3 , S1P 4 and S1P 5 (Mandala et al., 2002) . FTY720 causes immunosuppression by depleting peripheral blood lymphocytes, sequestering them in secondary lymphoid organs (Chiba et al., 1998) and preventing effector lymphocyte egress from draining lymph nodes to lymph and the blood compartment (Xie et al., 2003) . FTY720 also has pleiotropic cardiovascular effects. In stable renal transplant patients, it causes a dose-dependent transient bradycardia (Budde et al., 2003) and in anesthetized rats, either decreases or increases mean arterial pressure depending on the dose (Tawadrous et al., 2002) .
Studies on several S1P receptor agonists with varying degrees of selectivity (Hale et al., 2004a; Li et al., 2005) indicate that S1P 1 receptor agonism is strongly correlated with lymphocyte sequestration, while S1P 3 receptor agonism is associated with acute toxicity and bradycardia in rodents (Forrest et al., 2004; Sanna et al., 2004) . For example, S1P 1 -selective compounds A and B (Fig. 1 ) effectively alter lymphocyte trafficking and have much less potential to cause bradycardia and hypertension (Hale et al., 2004a; Li et al., 2005) . The toxicity and bradycardia associated with the non-selective agonists S1P and FY720-P were also abrogated in S1P 3 -/-mice confirming that S1P 3 agonism mediates these toxicities (Forrest et al., 2004; Sanna et al., 2004) . These findings led us to study how S1P 1 -selective agonists bind MOL# 29223 Page 5 to S1P 1 and S1P 3 .
GPCRs share a common 3D topology, consisting of seven trans-membrane helices (TMs) connected by three extracellular and three intracellular loops (Bosch et al., 2005; Fanelli and De Benedetti, 2005; van Rhee and Jacobson, 1996) . S1P receptors belong to the largest subfamily A of GPCRs which includes rhodopsin for which high resolution X-ray crystal structures are available (Edwards et al., 2004; Okada et al., 2002; Okada et al., 2004; Palczewski et al., 2000; Teller et al., 2001) . Although the rhodopsin molecules are in the unactivated 'dark state' in the structures, they provide attractive templates for homology modeling of family A GPCRs (Archer et al., 2003; Bosch et al., 2005; Fanelli and De Benedetti, 2005; Meng and Bourne, 2001) . 3 Parrill et al. proposed homology models for S1P 1 and S1P 4 receptors bound to natural ligands and agonists based on a theoretically calculated rhodopsin model (Inagaki et al., 2005; Jo et al., 2005; Parrill et al., 2000) . In their models, charged Arg and Glu residues at positions 3.28 and 3.29 on TM3 of S1P 1 and S1P 4 interact with the phosphate and ammonium moieties of the natural ligand S1P, respectively.
We describe molecular models of the S1P 1 and S1P 3 receptors bound to non-selective compounds S1P, FTY720-P or S1P 1 -selective compounds A or B based on the X-ray crystal structure of bovine rhodopsin (Palczewski et al., 2000) . Energy-minimized conformations of agonists were docked into the proposed S1P 1 binding pocket. Two groups of residues were identified based on the nature of their interactions with the docked agonists. The first consists of Arg120(3.28) and Glu121(3.29) identified by Parrill et al. (Inagaki et al., 2005; Jo et al., 2005; Parrill et al., 2000) . The second group consists of aromatic and hydrophobic residues on TM3, 5 and 6 that we propose form a hydrophobic binding pocket that interacts with the lipophilic chains of the agonists. One S1P 1 residue in this second group, Leu276(6.55), is not conserved in S1P 3 and our models predict that it contributes to the S1P 1 selectivity of compounds A and B. This S1P 1 residue and the corresponding Phe263 in S1P 3 were subjected to site-directed mutagenesis.
The mutant and wild type S1P receptors were expressed in Chinese hamster ovary (CHO) cells and
Materials and Methods
Sequence alignment of S1P receptors with bovine rhodopsin. The nomenclature proposed by van Rhee and Jacobson (van Rhee and Jacobson, 1996) is used to describe the amino acid residues in the S1P
receptors. Each residue is represented in two parts. The first part consists of the name and sequential number of an amino acid in a given S1P receptor sequence and is followed by a parenthesis with the second part, which is the index number defined by Ballesteros and Weinstein (Ballesteros and Weinstein, 1995) . In the Ballesteros-Weinstein system, each residue identifier begins with the TM number (e.g. 3 for TM3) followed by the position in the helix relative to the most highly conserved residue that is assigned number 50. For example, the charged residue pair in TM3 is represented as 3.28 and 3.29, i.e.
Arg120(3.28) and Glu121(3.29) in S1P 1 and Arg114(3.28) and Glu115(3.29) in S1P 3 .
Multiple sequence alignments of bovine rhodopsin, five human S1P receptors, three closely related human LPA receptors and some selected GPCR subfamily A sequences were generated with the program ClustalW (Thompson et al., 1994) . After computational alignment, manual adjustments were made to eliminate gaps in the TM regions.
Three-dimensional modeling of the S1P 1 receptor. The homology model of S1P 1 was generated with the program Quanta/Modeler (Accelrys Software Inc., San Diego, CA) based on the X-ray crystal structure of bovine rhodopsin (PDB entry 1F88) (Palczewski et al., 2000) . The amino-terminal 41 residues and carboxyl-terminal 51 residues of rhodopsin were excluded because of the lack of available template for these regions. The homology model was further refined using the Molecular Mechanics and Molecular Dynamics optimization to release the strain. The quality of the homology model was checked by Protein Health in Quanta (Accelrys Software Inc., San Diego, CA). The S1P 3 homology model was constructed in a similar fashion. Since S1P 1 and S1P 3 receptors share high sequence identity and similarity and the models were constructed using the same rhodopsin template, the models have very
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Page 8 similar topologies with a RMSD less than 1 Å for the receptor backbones. To minimize potential uncertainties introduced in modeling the flexible amino acid side chain structures, the S1P 1 homology model was used to dock agonists. The S1P 3 receptor was modeled based on the S1P 1 homology by mutating the non-conserved residues. This minimizes potential artifacts from the homology modeling while retaining the appropriate level of detail needed to select residues of interest identified through the docking studies.
Agonist docking in the S1P 1 receptor. The S enantiomer of FTY720-P is the most potent enantiomer of FTY720-P (Hale et al., 2004b) and was initially used in docking experiments because the affinities of the S1P enantiomers were unknown when these experiments were initiated. One hundred FTY720-P conformations were generated using our implementation of the distance geometry approach, which incorporates the theory and algorithm as previously described (Crippen and Havel, 1988) . The conformer set was energy minimized using a distance-dependent dielectric of 2r with the MMFFs force field (Halgren, 1996) . Manual docking placed the anionic phosphate and the positively charged ammonium of groups of FTY720-P close to the Arg120(3.28) and Glu121(3.29) on TM3. This docking placed the lipophilic chain of FTY720-P in a location similar to retinal in the rhodopsin-retinal complex. Since S1P and rhodopsin belong to GPCR subfamily A and the S1P receptor models were generated from and are similar to the rhodopsin crystal structure, the models place the lipophilic chains of FTY720-P in a hydrophobic pocket that is similar to that occupied by retinal between TM3, 5, 6 and 7. Ligand binding pockets lie between TM3, 5, 6 and 7 in many GPCRs and this is considered a common feature for family A GPCRs (Bondensgaard et al., 2004) . Docking models of the S1P 1 receptor with FTY720-P were obtained in a stepwise fashion in order to obtain the best docking pose and to minimize potential biases introduced by initially docking FTY720-P in the S1P 1 model manually. First, the hundred conformers of FTY720-P were docked into the putative binding pocket with their lipophilic chain superimposed onto the retinal structure by SQ calculations (Miller et al., 1999) . The
This article has not been copyedited and formatted. The final version may differ from this version. receptor complexes were energy optimized by MMFFs force field with the agonists fully optimized inside the binding pocket which allowed some degree of flexibility. The side chains of residues with any atom located within 5 Å of the agonists were fully minimized in conjunction with the agonists. Residues falling within 5 to 10 Å of the agonists were included in the calculations as rigid elements and the residues beyond a 10 Å cutoff from the agonist were ignored in the calculations. The total energy of the complex, the individual energies of the agonist and the receptor, and the interaction energy between the agonist and the receptor were calculated. The best docking mode was determined by selecting those poses with the most stabilizing interaction energy and minimal amount of strain on the agonist and also by visual inspection of the interactions. This receptor-agonist model was used as a second template to superpose another hundred conformers, followed by the same procedure of energy optimization of complexes. The cycles continued until the docking pose could not be improved energetically. The docking models of S1P 1 receptor with S1P, compounds A and B were derived from the final docking model of S1P 1 receptor with FTP720-P, through similar cycles of conformational searches and energy minimizations, superposition onto the template, energy optimizations of complexes and determinations of best docking poses by energy and visual check of interactions. Other docking programs, such as ICM (Molsoft LLC, San Diego, CA) were used to generate FTY720-P docking poses in the S1P 1 receptor but did not generate more energetically favorable or new models.
Synthesis. The syntheses of compound A and B have been described previously (Hale et al., 2004a; Li et al., 2005) . All compounds were characterized by 1 H NMR, MS and HPLC and were judged to be >95% pure.
Cloning the human S1P 1 and S1P 3 Receptors into Expression Plasmids. An N-terminal Flag-tagged human S1P 3 receptor sequence was amplified from an expression vector provided by Kevin Lynch (University of Virginia, Charlottesville, VA) by PCR amplification using the primer set SAP470 (5'-GAATTCGCCACCATGGATTACAAGGATGACG-3') and SAP471 (5'-MOL# 29223
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protocols. The mutagenic and selection primers and restriction enzyme used to generate the S1P 1 mutation were SAP486 (5'-phosphate-CTCTTCATCCTGTTCCTGCTGGATGTG-3'), SAP505 (5'-phosphate-ATCCCGTATTGATGCCGGGCAAGAGC-3') and BsaHI, respectively. The mutagenic and selection primers and restriction enzyme used to generate the S1P 3 mutation were SAP486 (5'-phosphate-CTCTTCATCCTGTTCCTGCTGGATGTG-3'), SAP506 (5'-phosphate-GACTGGTGAGTATTCAACCAAGTCATT-3') and ScaI, respectively. The coding sequences of the S1P 1 Leu276Phe and S1P 3 Phe263Leu mutants were confirmed by DNA sequence analysis. For expression studies, the S1P 1 Leu276Phe mutant was cloned into pCDEF3neo as a BamHI-NotI fragment.
The S1P 3 Phe263Leu mutant was subcloned into the EcoRI-NotI restriction sites of vector pCDEF3neo. 10% charcoal/ dextran treated fetal bovine serum after selection with G418. Stable CHO cell lines expressing the S1P 1 and S1P 3 receptors were identified in 33 P-S1P binding assays using whole cells and assay conditions described below.
Preparation of membranes from whole cells. Cell membranes were prepared from whole cells, as described previously (Mandala et al., 2002) . Protein concentrations were determined using the Biorad Bradford protein assay kit II (Biorad, Hercules, CA). 
Measurements of 35 S-GTPγS binding.
35 S-GTPγS (1250 Ci/mmole) binding was assayed in membranes (3 µg) prepared from CHO cell lines as described previously (Mandala et al., 2002) . The reactions were incubated at 22 ºC for one hour and washed six times with distilled water using a Packard This article has not been copyedited and formatted. The final version may differ from this version. of the maximal increase obtained using 5 µM S1P on the wild type S1P 1 or S1P 3 receptors. S1P 1 and S1P 3 antisera. The C-terminal S1P 1 rabbit antiserum MS1766 has been described previously (Forrest et al., 2004) . A peptide in the N-terminus of human S1P 3 (REHYQYVGKLAGRLKEASE) was synthesized (SynPep Corp, Dublin, CA), conjugated to KLH, and used to immunize rabbits (Covance Research Products, Denver, PA). Specific IgG fractions were affinity purified using the immunizing peptide and tested by western hybridization against a panel of human, mouse and rat S1P receptors. The S1P 3 antiserum MS2284 was specific for the human S1P 3 receptor.
Confocal Microscopy Studies of S1P 1 and S1P 3 Receptor Expression. Stable CHO clones expressing the receptors were plated in four chambers of the Lab-Tek II Chamber #1.5 German Coverglass System at a density of 40,000 cells per chamber, in Iscoves modified Dulbecco's medium with sodium pyruvate, HT and 10% charcoal/ dextran treated fetal bovine serum, and 25 mM Hepes buffer, pH 7.5. Cells were allowed to adhere for 24 hours at 37 ºC. Growth medium was removed and cells were washed / equilibrated with FACS buffer (1x PBS containing 2.5% charcoal/ dextran treated fetal bovine serum, 25
mM Hepes, and 0.05% NaN 3 ). To detect S1P 3 , adherent cells were blocked with goat IgG blocking antibody (MP Biomedicals, Irvine, CA) at 100 µg / ml in FACS buffer. After 10 minutes of incubation at This article has not been copyedited and formatted. The final version may differ from this version. Hybridization of rabbit S1P 1 antiserum (MS1766) (1:1000 dilution) or rabbit S1P 3 antiserum (MS2844)
(1:3000) was performed in Starting Block buffer at 4 ºC for 16 hours. After three 5 minute washes, the membranes were incubated with a stabilized goat anti-rabbit IgG-HRP conjugated antibody (Pierce, Rockford, IL) at a 1:3000 dilution (S1P 1 ) or 1:20,000 dilution (S1P 3 ) for one hour at 22 ºC. Hybridization was detected with the Pierce ECL-femto kit following the manufacturer's protocol, using CL-X Posure film (Pierce, Rockford, IL).
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Homology modeling of the S1P 1 and S1P 3 receptors. To model the structures of the S1P receptors, we aligned their primary amino acid sequences with other members of the GPCR A subfamily in order to optimize the sequence alignment. Bovine rhodopsin was used as the structural template for the homology model. The alignment of TM3, 4, 5, 6 and 7 of S1P receptors with bovine rhodopsin is illustrated in Fig.   2 . The most conserved residues in the family A GPCRs are conserved in six of the seven TM domains in S1P receptors, except TM5. The most highly conserved Pro (5.50) in TM5 of the family A GPCRs is replaced by hydrophobic residues in the S1P receptors, i.e. Leu in S1P 1 , Ile in S1P 2 , S1P 3 and S1P 5 , and
Val in S1P 4 (Fig. 2) . However, another highly conserved residue, Tyr (5.58) (Bosch et al., 2005) , is present in all five S1P receptors. In many of the family A GPCRs, a disulfide bond exists between TM3
and the second extracellular loop between TM4 and TM5 (Bosch et al., 2005) . For example, in bovine rhodopsin, the disulfide bond is formed between residue Cys110(3.25) and Cys187 (Palczewski et al., 2000) . This disulfide bond does not exist in the S1P receptors which contain a Trp in TM3 in place of Cys at position 3.25.
The S1P 1 and S1P 3 receptors share the highest degree of amino acid sequence relatedness in the S1P receptor family, with approximately 50% of the residues identical, another 20% of the residues strongly similar and more than 10% of the residues weakly similar. Since the S1P 1 and S1P 3 receptors are highly conserved, the S1P 1 homology model was used for docking of agonists. The S1P 1 homology model displays a three dimensional structure similar to bovine rhodopsin, with a seven TM helical bundle and a short cytoplasmic helix (Fig. 3) . The S1P 3 receptor was modeled based on the S1P 1 homology model, focusing on the non-conserved residues.
Structure of the agonist binding pocket of the S1P 1 and S1P 3 receptors. The compounds used in this This article has not been copyedited and formatted. The final version may differ from this version. study included the natural ligand S1P, FTY720-P which is a phosphate ester of FTY720, and compounds A and B which are S1P 1 -selective agonists (Fig. 1) . These compounds share common structural characteristics including charged head groups and long lipophilic side chains. The S-enantiomeric phosphate ester of FTY720-P was used to generate models of agonist-bound S1P 1 receptor complexes for several reasons. It is a more potent agonist of the human S1P 1 receptor than the R-enantiomer (Hale et al., 2004b) and is an agonist of S1P 3 , S1P 4 and S1P 5 . The R-enantiomer is a full agonist of S1P 1 and S1P 4 but it's potency at these receptors is lower and it is an antagonist of S1P 3 and S1P 5 . At the time these experiments were initiated, the agonist/antagonist activities and affinities of the enantiomeric phosphate esters of S1P against the S1P receptor family were also unknown.
In the agonist docking models, S1P, FTY720-P and the S1P 1 -selective compounds A and B, bind to a common pocket that contains conserved receptor-agonist interactions. The preferred docking mode for agonists in these models is depicted in Fig. 3 , in which FTY720-P is illustrated. The agonists are bound in the upper half of the TM helical bundle, towards the extracellular surface. The agonists have an extended conformation in a narrow binding pocket and are surrounded by residues mainly from TM3, 5
and 6, and a few residues from TM4 and 7. Amino acid residues with any atom located within 4Å of ligands in the docking models are indicated with asterisks in Fig. 2 and are highlighted in green or yellow (Leu276(6.55)) in Figure 3 .
Further examination of receptor residues within 4Å of the agonists in the binding pocket identified two groups of interactions (Fig. 4) . The first group consists of the charged residues on TM3, Arg120(3.28) and Glu121(3.29), identified by Parrill et al. (Inagaki et al., 2005; Jo et al., 2005; Parrill et al., 2000) .
These receptor residues interact with the charged head groups of agonists in our models. For example, the distance between the anionic phosphate group of FTY720-P and the positively charged side chain of Arg120(3.28) of S1P 1 is approximately 2.5 Å; similarly, the ammonium of FTY720-P is within 2.6 Å of the negatively charged side chain of Glu121(3.29) (Fig. 4B) . The second group of interactions consists of This article has not been copyedited and formatted. The final version may differ from this version. Leu276(6.55) . Eight of these residues are conserved between S1P 1 and S1P 3 receptors. The ninth residue, Leu276(6.55) in S1P 1 is replaced by Phe263(6.55) in S1P 3 (Figure 2 ).
In the S1P 1 -agonist docking models, Leu276(6.55) forms van der Waals interactions with the phenyl ring and azetidine of compounds A and B (Fig. 4C and 4D ). In the S1P 3 model, the bulkier Phe263 residue reduces the size of the binding pocket and sterically hinders binding of compounds A and B to the receptor. These results suggested that the Leu276/Phe263 residues contribute to the S1P 1 / S1P 3 selectivity of compounds A and B. S1P 1 and S1P 3 receptor binding assays. We developed a competitive receptor binding assay using CHO cells transiently transfected with the S1P 1 and S1P 3 receptors in order to rapidly assay agonist binding to the receptor mutants. In this assay, S1P inhibited the binding of [ 33 P]-S1P to the S1P 1 and S1P 3 receptors with high affinity (Fig. 5A and B) . When assayed in binding assays using transiently transfected receptors, compound A bound S1P 1 with high affinity and exhibited selectivity for S1P 1 over S1P 3 (Fig. 5) .
To investigate the role of the S1P 1 Leu276 and S1P 3 Phe263 residues in the selectivity of compound A, we constructed S1P 1 Leu276Phe and S1P 3 Phe263Leu mutant receptors by site-directed mutagenesis and assayed the abilities of the receptors to bind S1P and compound A in transiently transfected cells. The S1P 1 Leu276Phe and S1P 3 Phe263Leu mutants bound S1P with high affinities similar to those of the wild type receptors (Fig. 5) . The S1P 1 -selective compound A bound to the S1P 1 Leu276Phe mutant receptor with lower affinity compared to the wild type S1P 1 receptor. Conversely, the S1P 3 Phe263Leu mutant receptor bound to compound A with higher affinity compared to the wild type S1P 3 receptor.
Wild-type and mutant S1P receptors are expressed on the cell surface of stable cell lines. Stable This article has not been copyedited and formatted. The final version may differ from this version. CHO cell lines expressing the wild type and mutant S1P 1 and S1P 3 receptors were generated to expand the characterization of the mutant S1P 1 Leu276Phe and S1P 3 Phe263Leu receptors. Expression patterns of the wild type and mutant receptors in the stable cells lines were characterized by western hybridization and confocal microscopy. Murine S1P 1 is N-glycosylated in the ectodomain on an asparagine residue in CHO cell lines over expressing the receptor and this residue is conserved in S1P 2 , S1P 4 and S1P 5 (Kohno et al., 2002) . The amino-terminal ectodomains of murine S1P 1 and S1P 3 are also truncated in over expressing CHO cells (Kohno and Igarashi, 2003) . We have observed similar findings with the stable cell lines expressing the human wild type and mutant S1P 1 and S1P 3 receptors. The predicted size of the flagtagged human S1P 1 receptors in these experiments is 44.3 kDa. The S1P 1 -specific antiserum recognize Leu276Phe receptors expressed in CHO cells indicate that these receptors are glycosylated. We have also observed that the wild type and mutant S1P 1 receptors do not cross-react with an antibody that recognizes the Flag tag (data not shown) indicating that human S1P 1 receptors are also truncated at the Nterminus. Proteins of approximately 47.7 kDa were detected in membranes from the cell lines expressing the S1P 3 wild type and Phe263Leu receptors ( Figure 6B ). The predicted sizes of the flag-tagged S1P 3 receptors are 43.8 kDa suggesting the receptors are migrating anomalously or are post-translationally modified. The wild type and mutant S1P 3 receptors were also not recognized by the Flag antibody (data not shown) indicating that the human S1P 3 receptors are also truncated at the N-terminus.
We also examined localization of the wild type and mutant receptors by confocal microscopy (Fig. 7) .
The S1P 1 antiserum recognized S1P 1 wild type or Leu276Phe mutant receptors at the cell surface indicating that the Leu276Phe mutation did not alter trafficking of the receptor in cells. Similar results
This article has not been copyedited and formatted. The final version may differ from this version. To examine the contribution of S1P 1 Leu276 and S1P 3 Phe263 residues to S1P 1 -selective compounds A and B, we determined the Log IC 50 s of these compounds for the wild type and mutant S1P 1 and S1P 3 receptors (Table 2 ). Compound A bound to the wild type S1P 1 receptor with approximately 13 fold higher affinity than to the S1P 1 Leu276Phe receptor. The Log IC 50 of compound A on the mutant receptor was -7.37 M. The S1P 1 -selective agonist compound B bound to wild type S1P 1 receptor with approximately 40 fold higher affinity than to the Leu276Phe mutant with a Log IC 50 of -7.33 M. In contrast, the S1P 1 -selective compounds bound with approximately 10 and 151-fold higher affinities to the mutant S1P 3 Phe263Leu receptor when compared to the wild type receptor. The Log IC 50 s of compounds A and B for the S1P 3 Phe263Leu mutant were -6.71 and -7.56 M, respectively.
The potencies and efficacies of S1P, FTY720-P and compounds A and B for the wild type and mutant receptors were also evaluated in [ 35 S]-GTPγS binding assays ( Figure 8 and Table 3 ). The basal activities (mean + S.E.) of the S1P 1 wild type and mutant receptors were 1102 + 137 and 862 + 51 fmoles/mg, respectively and S1P activated the receptors with similar affinities (Log EC 50 of -7.48 and -7.58 M, respectively). In our in vitro experiments measuring [ 35 S]-GTPγS binding, the potency of S1P as an agonist of the S1P wild type and mutant receptors is approximately 50 fold lower than the affinity of S1P for these receptors in competition binding assays. This decrease in potency is due a phosphatase activity in CHO membrane preparations over expressing the S1P 1 receptor (J. Milligan, G.J. Shei and S. Mandala, data not shown). This activity hydrolyzes S1P resulting in a loss of potency of the natural agonist in the S1P 3 receptors were -8.45 and -8.64 M, respectively, and S1P activated the S1P 3 mutant receptor efficiently (Emax 82%). The S1P 3 Phe263Leu mutation had minimal effects on the basal activity of the receptor (Figure 8 ). Although FTY720-P was a potent and efficacious agonist of the mutant S1P 1
Leu276Phe receptor (Log EC 50 = -8.76 M, Emax = 109%), the compound was a 6-fold more potent agonist of the wild type receptor (Log EC 50 = -9.54 M, Emax = 95%). FTY720-P was also a potent agonist of the wild type and mutant S1P 3 receptors with Log EC 50 values of -8.87 and -9.07 M,
respectively. This synthetic agonist also activated the wild type and mutant S1P 3 receptors effectively
with Emax values of 106 and 93%, respectively.
The S1P 1 Leu276Phe and S1P 3 Phe263Leu mutations had significant affects on the agonist potencies of compounds A and B (Figure 8 and Table 3 ). The S1P 1 -selective compounds A and B were potent and efficacious agonists of the wild type S1P 1 receptor. The Log EC 50 values of the compounds were -8.81
and -9.61 M, respectively. The potencies of S1P 1 -selective compounds A and B for the S1P 1 Leu276Phe mutant were lower when compared to the wild type receptor with Log EC 50 s of -6.90 and -6.66 M, respectively. Despite a decrease in potency, compounds A and B activated the mutant S1P 1 receptor effectively with Emax values of 103 and 116%, respectively. In contrast, compounds A and B were more potent agonists of the S1P 3 Phe263Leu mutant when compared to the wild type S1P 3 receptor. The Log EC 50 values of the compounds against the wild type S1P 3 receptor were -6.34 and -5.85 M, respectively.
Both S1P 1 -selective agonists were more potent agonists of the S1P 3 Phe263Leu receptor with Log EC 50 s of -7.97 and -8.98 M, respectively. Both compounds A and B were also effective agonists of the wild type and mutant S1P 3 receptors with Emax values ranging from 80-128%.
Discussion
The S1P receptors share high homology in their primary sequences and, as expected, the agonist binding pockets of the S1P 1 and S1P 3 receptors predicted by our modeling studies overlap and share conserved residues that interact with agonists. This is consistent with findings that many S1P receptor agonists do not exhibit significant receptor subtype selectivity. The potential clinical advantage of S1P receptor agonists lacking S1P 3 activity has prompted development of S1P 1 / S1P 3 selective agonists and led us to study receptor-agonist interactions and receptor structural features that contribute to S1P 1 /S1P 3 selectivity. Our modeling studies and mutagenesis experiments indicate that Leu276(6.55) in S1P 1 and Phe263(6.55) in S1P 3 are critical residues that contribute to the S1P 1 -selectivity of compounds A and B.
In our docking models, the agonists bind S1P 1 in a narrow cavity located in the upper half of the seven TM helical bundle. The binding pocket consists of residues located on TM3, 5, 6 and 7. Similar pockets have been identified in many GPCRs by mutagenesis studies and are regarded as a common feature for family A GPCRs (Bondensgaard et al., 2004) . Interactions between charged residues on TM3 and charged agonists or antagonists are found in many GPCRs (Feighner et al., 1998; Shin et al., 2002) . The importance of S1P interactions with Arg120(3.28) and Glu121(3.29) in the S1P 1 receptor were revealed by mutagenesis studies directed by a model generated from a theoretically-calculated structure of bovine rhodopsin (Parrill et al., 2000) . Our model, which is based on the X-ray structure of bovine rhodopsin in the dark state, and mutagenesis studies on the human S1P 1 and S1P 3 receptors confirm these findings (data not shown). The charged residues at the top of the binding pocket interact with the counter-ions in the charged head groups of the agonists. These conserved residues (Fig. 2 ) play important roles in recognizing charged agonists in all S1P receptors. Arg120(3.28) is also conserved in LPA receptors but Glu121(3.29) is substituted with a Gln in LPA receptors. These LPA receptor residues are key determinants of their ligand specificity (Wang et al., 2001 ).
This article has not been copyedited and formatted. The final version may differ from this version. The hydrophobic domain of the proposed binding pocket of the S1P 1 receptor is adjacent to the lipophilic side chain of the agonists used in this study. Based on our docking models, a group of aromatic and hydrophobic residues line the wall of the binding pocket. These residues are located deep in the pocket and provide important interactions with the lipophilic side chain of the agonists. Some of these residues, Phe125(3.33), Phe273(6.52) and Trp269(6.48), have also been proposed to interact with S1P 1 agonist SEW2871 (Jo et al., 2005) . S1P 1 residues Phe210(5.47), Phe265(6.44) and Trp269(6.48) are among a group of highly conserved residues in many family A GPCRs (Bondensgaard et al., 2004) .
Previous mutagenesis studies illustrate the importance of aromatic residues in TM3 and 6 in the binding and activation of GPCRs by agonists (Holst et al., 2004; Renzetti et al., 1999; Spalding et al., 1998) .
Our examination of the predicted agonist binding pockets of S1P 1 and S1P 3 identified a non-conserved Leu at position 6.55 in S1P 1 . Four of five S1P receptors also contain a Leu at this position while S1P 3 contains a Phe residue at the equivalent position. In our models, Leu276 in S1P 1 and Phe263 in S1P 3 affect the sizes of the binding pockets. The volume of the Phe aromatic side chain is about 25% larger than that of the aliphatic Leu side chain, making the S1P 3 binding pocket more crowded than the S1P 1 pocket. In the S1P 1 docking models, Leu276(6.55) is close to the phenyl ring and azetidine of S1P 1 -selective compounds A and B (Fig. 4C and 4D ). The rigidity of these regions of compounds A and B makes it difficult for them to assume conformations that fit in the smaller binding pocket of the S1P 3 receptor, explaining their S1P 1 selectivity. When Leu276(6.55) is replaced with a Phe in the S1P 1 model, the binding pocket is smaller because of the bulkier size of the Phe side chain.
To test this model, we constructed S1P 1 and S1P 3 receptor mutants in which the Leu276 and Phe263 residues were exchanged and examined their expression and activity in western hybridization, confocal microscopy and radioligand binding experiments. These experiments indicate that the S1P 3 wild and mutant receptors are over expressed on the surface of the stable CHO cell lines at similar densities and that both receptors bind S1P with high affinity. The K d values of S1P for both receptors are This article has not been copyedited and formatted. The final version may differ from this version. The competitive ligand binding and agonist functional studies comparing the S1P 1 and S1P 3 wild type and mutant receptors confirm the predictions of the molecular models we developed for these receptors.
The S1P 1 Leu276Phe mutant has a significantly reduced affinity for S1P 1 -selective compounds A and B, and both of these agonists activate the S1P 1 mutant with much poorer potencies. On the other hand, substituting Phe263(6.55) of the S1P 3 receptor with Leu in the S1P 3 receptor enlarges the binding pocket of this mutant S1P 3 receptor, leading to an increase in the binding affinity and agonist potency of compounds A and B. This prediction was also verified experimentally with the S1P 3 Phe263Leu mutant.
Additionally, our conformational analyses of compounds A and B indicate that compound B is more rigid than compound A (data not shown), making it more difficult to assume a conformation that fits the binding pocket of the S1P 3 receptor and more susceptible to changes at Leu276 and Phe263 of the S1P 1 and S1P 3 receptors, respectively. Our in vitro analyses of the interactions of compounds A and B with the wild type and mutant receptors demonstrate that the mutations have more dramatic effects on the binding affinity and agonist potency of compound B.
In contrast to S1P 1 -selective compounds A and B, S1P contains a long, highly flexible alkyl side chain that easily adopts a conformation to bind to S1P 1 and S1P 3 . It binds to both receptors with comparable affinities and is not sensitive to the Leu and Phe substitution mutations we constructed in S1P 1 and S1P 3 .
FTY720-P is also a high-affinity agonist of S1P 1 and S1P 3 with a slightly higher agonist potency against This article has not been copyedited and formatted. The final version may differ from this version. Downloaded from S1P 1 . Our models predict that FTY720-P has a higher potency for S1P 1 because it contains a phenyl ring and prefers a larger binding pocket. The phenyl ring of FTY720-P is four bonds away from the positively charged ammonium group and seven bonds away from the negatively charged phosphate group. The longer linker between the charged head group and the phenyl ring of FTY720-P is more flexible than the azetidine moiety in S1P 1 -selective compounds A and B. The models suggest that this flexibility is the reason FTY720-P is affected less by changes of the Leu276 and Phe263 residues in the binding pockets of S1P 1 and S1P 3 . Although significant changes in FTY720-P binding affinity for the mutant or wild type receptors were not observed in competition binding assays, the S1P 1 Leu276Phe mutation did confer a statistically significant change in agonist potency measured in vitro. FTY720-P activates the wild type S1P 1 receptor 6-fold more potently than the S1P 1 Leu276Phe receptor, which contains a significantly smaller binding pocket.
These models predict that residues Leu276(6.55) and Phe263(6.55) are important contributors to S1P 1 and S1P 3 specificities of compounds A and B. However, the changes in agonist binding affinities and potencies observed with these mutations do not fully interconvert the pharmacological profiles of either agonist, indicating that other residues within the binding pocket also contribute to the specificities of these subtype-selective agonists. There are seven non-conserved residues in S1P 1 and S1P 3 within 4 Å of the predicted agonist binding pocket (Val3.40Thr, Val5.46Ile, Leu5.50Ile, Leu6.41Val, Ala6.49Ser, Leu6.55Phe and Leu7.39Ile) . Except for Leu276Phe, these residues are predicted to have smaller effects on the specificities of compounds A and B based on their positions and orientations. Combining the S1P 1 Leu276Phe or S1P 3 Phe263Leu mutations with amino acid substitutions in the other six non-conserved residues in S1P 1 and S1P 3 in the predicted agonist binding pocket may interconvert the pharmacological profiles of these agonists completely. Models of GPCR-agonist complexes based on X-ray crystal structures of rhodopsin in the unactivated 'dark state' also have an inherent bias that might mask important receptor interactions with agonists.
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Page 28 Our integrated molecular modeling and site-directed mutagenesis studies of the S1P 1 and S1P 3 receptors bound to non-selective and S1P 1 -selective agonists provide additional insights into the nature of different S1P receptor-agonist interactions and identify an important pair of residues in S1P 1 and S1P 3 that contribute significantly to receptor subtype selectivity of compounds A, B and FTY720-P. These findings provide a molecular basis for understanding S1P 1 /S1P 3 subtype-selectivity of these S1P receptor agonists, which should aid development of more selective S1P 1 receptor agonists with immunosuppressive properties and improved safety profiles.
Footnotes
Legends for Figures   Fig. 1 . The chemical structures of S1P, FTY720, FTY720-P and compounds A and B. Asterisks above the alignments denote residues predicted to be located within 4Å of ligand in the docking models of S1P 1 with S1P, FTY720-P, compounds A or B. antiserum. The following amounts of membrane protein were eletrophoresed on the gel: 1 µg of S1P 1 ; 0.2 µg of S1P 1 Leu276Phe; 1 µg of S1P 3 ; 1 µg of S1P 3 Phe263Leu; 1 µg of CHO control membrane protein.
(B) Western hybridization analysis of wild type and mutant S1P 1 and S1P 3 receptors expressed in stable CHO cell lines with S1P 3 antiserum. The following amounts of membrane protein were electrophoresed: 4 µg of S1P 1 ; 1 µg of S1P 1 Leu276Phe; 1 µg of S1P 3 ; 1 µg of S1P 3 Phe263Leu; 1 µg of CHO control membrane protein.
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